Mr. Cole has served as the Chief Financial Officer of Genomic Life, Inc. since February 2022. Previously, he served as Executive Advisor of Exact Sciences Corporation since April 2020, and from November 2019 until April 2020 he served as its GM, Precision Oncology. Prior to that, Mr. Cole served as Chief Financial Officer of Genomic Health, Inc., a molecular diagnostics company, from July 2014 to November 2019 and from July 2004 to January 2011, and as Chief Operating Officer of Genomic Health from January 2009 until March 2018, when it was acquired by Exact Sciences. Mr. Cole served as Secretary of Genomic Health from February 2005 until July 2012. From December 1997 to May 2004, he served in various roles at Guidant Corporation, a medical device company, most recently serving as Vice President, Finance and Business Development for the Endovascular Solutions Group. From January 2001 until May 2004, he served as Vice President, Finance and Chief Financial Officer of Endovascular Technologies, Inc., a medical device company that was acquired by Guidant Corporation. Previously, Mr. Cole served as Vice President, Finance and Chief Financial Officer of Applied Biosystems Incorporated, a life sciences systems company. Mr. Cole serves on the boards of Castle Biosciences, a skin cancer diagnostics company, and Genomic Life, Inc. He also serves as Vice Chairman of the Board of Trustees of Biola University. Mr. Cole holds a B.S. in Business from Biola University and an M.B.A. from San Jose State University.
What is G. Bradley Cole's net worth?
The estimated net worth of G. Bradley Cole is at least $844.50 thousand as of July 29th, 2026. Mr. Cole owns 11,672 shares of Kiniksa Pharmaceuticals International stock worth more than $844,504 as of August 3rd. This net worth evaluation does not reflect any other assets that Mr. Cole may own. Learn More about G. Bradley Cole's net worth.
How do I contact G. Bradley Cole?
Has G. Bradley Cole been buying or selling shares of Kiniksa Pharmaceuticals International?
Over the course of the past ninety days, G. Bradley Cole has sold $299,092.39 in shares of Kiniksa Pharmaceuticals International stock. Most recently, G Bradley Cole sold 3,673 shares of the business's stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a transaction totalling $299,092.39. Following the completion of the sale, the director now directly owns 11,672 shares of the company's stock, valued at $950,450.96. Learn More on G. Bradley Cole's trading history.
Who are Kiniksa Pharmaceuticals International's active insiders?
Kiniksa Pharmaceuticals International's insider roster includes G. Bradley Cole (Director), Thomas Malley (Director), Michael Megna (Group Vice President of Finance and Chief Accounting Officer), Ross Moat (Executive Vice President, Chief Commercial Officer), John Paolini (Executive Vice President, Chief Medical Officer), Sanj Patel (CEO and Chairman of the Board), Barry Quart (Director), Mark Ragosa (CFO), and Eben Tessari (https://monarchcasino.com/corporategovernance_boardofdirectors.asp). Learn More on Kiniksa Pharmaceuticals International's active insiders.
Are insiders buying or selling shares of Kiniksa Pharmaceuticals International?
In the last year, insiders at the sold shares 47 times. They sold a total of 1,801,107 shares worth more than $76,332,385.25. The most recent insider tranaction occured on July, 29th when Director G Bradley Cole sold 3,673 shares worth more than $299,092.39. Insiders at Kiniksa Pharmaceuticals International own 52.0% of the company.
Learn More about insider trades at Kiniksa Pharmaceuticals International. Information on this page was last updated on 7/29/2026.
